Opeolu Adeoye1, Richard Hornung, Pooja Khatri, Dawn Kleindorfer. 1. UC Neuroscience Institute, Department of Emergency Medicine, 231 Albert Sabin Way, ML 0769, University of Cincinnati Medical Center, Cincinnati, OH 45267-0525, USA. opeolu.adeoye@uc.edu
Abstract
BACKGROUND AND PURPOSE: Recombinant tissue-type plasminogen activator (rtPA) is the only approved therapy for acute ischemic stroke (AIS). In 2004, 1.8% to 2.1% of AIS patients in the United States received rtPA. Given incentives from regulatory agencies and payors to increase rtPA use, we hypothesized that rtPA use in the United States would increase from 2005 to 2009. METHODS: AIS cases were defined by exclusion of hemorrhagic stroke and transient ischemic attack International Classification of Diseases 9th revision codes (430, 431, 432, and 435) from diagnosis-related groups 14, 15, 524, and 559 discharges. Patients receiving thrombolytics were identified using International Classification of Diseases 9th revision code 99.10 (Medicare Provider and Analysis Review and Premier databases) and pharmacy billing records (Premier). Change over time and differences between databases were tested using negative binomial regression. RESULTS: Within Medicare Provider and Analysis Review, thrombolytic use increased from 1.1% in 2005 to 3.4% in 2009 (P<0.001 for trend). Within Premier, thrombolytic use increased from 1.4% in 2005 to 3.7% in 2009 for all cases (P<0.001). Analysis of pharmacy billing records in Premier for 50-mg or 100-mg doses of rtPA showed that 3.4% of AIS cases were treated in 2009. Inclusion of patients with transient ischemic attack or hemorrhagic stroke International Classification of Diseases 9th revision codes who received any thrombolytic as "ischemic stroke patients receiving rtPA" changed the rate of thrombolysis to 5.2%. CONCLUSIONS: In 2009, 3.4% to 5.2% of AIS patients in the United States received thrombolytics, approximately double the rate of treatment in 2005. Rapid recognition and transport and quick treatment in the emergency department remain goals for further improving treatment rates.
BACKGROUND AND PURPOSE: Recombinant tissue-type plasminogen activator (rtPA) is the only approved therapy for acute ischemic stroke (AIS). In 2004, 1.8% to 2.1% of AIS patients in the United States received rtPA. Given incentives from regulatory agencies and payors to increase rtPA use, we hypothesized that rtPA use in the United States would increase from 2005 to 2009. METHODS: AIS cases were defined by exclusion of hemorrhagic stroke and transient ischemic attack International Classification of Diseases 9th revision codes (430, 431, 432, and 435) from diagnosis-related groups 14, 15, 524, and 559 discharges. Patients receiving thrombolytics were identified using International Classification of Diseases 9th revision code 99.10 (Medicare Provider and Analysis Review and Premier databases) and pharmacy billing records (Premier). Change over time and differences between databases were tested using negative binomial regression. RESULTS: Within Medicare Provider and Analysis Review, thrombolytic use increased from 1.1% in 2005 to 3.4% in 2009 (P<0.001 for trend). Within Premier, thrombolytic use increased from 1.4% in 2005 to 3.7% in 2009 for all cases (P<0.001). Analysis of pharmacy billing records in Premier for 50-mg or 100-mg doses of rtPA showed that 3.4% of AIS cases were treated in 2009. Inclusion of patients with transient ischemic attack or hemorrhagic stroke International Classification of Diseases 9th revision codes who received any thrombolytic as "ischemic strokepatients receiving rtPA" changed the rate of thrombolysis to 5.2%. CONCLUSIONS: In 2009, 3.4% to 5.2% of AIS patients in the United States received thrombolytics, approximately double the rate of treatment in 2005. Rapid recognition and transport and quick treatment in the emergency department remain goals for further improving treatment rates.
Authors: Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett Journal: Circulation Date: 2010-02-23 Impact factor: 29.690
Authors: Adnan I Qureshi; M Fareed K Suri; Abu Nasar; Wei He; Jawad F Kirmani; Afshin A Divani; Charles J Prestigiacomo; Ronald B Low Journal: Neurosurgery Date: 2005-10 Impact factor: 4.654
Authors: Dawn Kleindorfer; Brett Kissela; Alex Schneider; Daniel Woo; Jane Khoury; Rosemary Miller; Kathleen Alwell; James Gebel; Jerzy Szaflarski; Arthur Pancioli; Edward Jauch; Charles Moomaw; Rakesh Shukla; Joseph P Broderick Journal: Stroke Date: 2004-01-22 Impact factor: 7.914
Authors: Dawn Kleindorfer; Christopher J Lindsell; Lawrence Brass; Walter Koroshetz; Joseph P Broderick Journal: Stroke Date: 2008-01-31 Impact factor: 7.914
Authors: Lesli E Skolarus; Jillian B Murphy; Mackenzie Dome; Marc A Zimmerman; Sarah Bailey; Sophronia Fowlkes; Lewis B Morgenstern Journal: Health Promot Pract Date: 2014-11-03
Authors: Steven C Cramer; Dana Stradling; David M Brown; Ignacio M Carrillo-Nunez; Anthony Ciabarra; Michael Cummings; Richard Dauben; David L Lombardi; Nirav Patel; Elizabeth N Traynor; Stephen Waldman; Ken Miller; Samuel J Stratton Journal: Stroke Date: 2012-01-26 Impact factor: 7.914
Authors: Aravind Ganesh; Marie Camden; Patrice Lindsay; Moira K Kapral; Robert Coté; Jiming Fang; Brandon Zagorski; Michael Douglas Hill Journal: CMAJ Open Date: 2014-10-01